Luke Beshar

Track

Insider profile

Currently holds positions in Protara Therapeutics Inc, Trillium Therapeutics Inc and Regenxbio Inc

Performance

Overall performance
2.4
Performance over holding periods
2.4
30 days 90 days 120 days
Average return 7% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
3 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chairman of the Board Protara Therapeutics Inc Jan. 9, 2020 -
Independent Director Trillium Therapeutics Inc March 10, 2014 -
Independent Director Regenxbio Inc April 1, 2015 -
Chairman of the Board Entera Bio Ltd Dec. 1, 2016 - Aug. 9, 2018
Director Entera Bio Ltd Dec. 1, 2015 - Dec. 1, 2016
Chief Financial Officer, Executive Vice President Shire-Nps Pharmaceuticals Inc Jan. 1, 2011 - Feb. 20, 2015
Luke Beshar's trades of Protara Therapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
96.23
Quantity 20,552 +9.4%
Value US$876,067
Transaction date
Purchase
Price
127.79
Quantity 41,068 +44.4%
Value US$2,551,518
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2022-07-05 2022-06-30
B Purchase
20,552 +9.4%
96.23
US$876,067 		20,552 +9.4% 96.23 US$876,067
2022-03-16 2022-03-14
B Purchase
41,068 +44.4%
127.79
US$2,551,518 		41,068 +44.4% 127.79 US$2,551,518
2022-03-14 2022-03-10
B Purchase
35,217 -46.3%
235.87
US$532,631 		35,217 -46.3% 235.87 US$532,631